First patient dosed in Scancell’s clinical trial for multiple cancers
First-in-human clinical trial in patients with triple negative breast cancer, ovarian cancer, head and neck cancer and renal cancer
Read More
Tag: Scancell
Scancell receives funding for COVID-19 vaccine development
It is hoped that the vaccine will generate protection not only against SARS-CoV-2, but also against new strains of coronavirus that may arise in the future
Read More
Scancell kicks off COVID-19 vaccine development
The firm’s DNA vaccines target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells
Read More
Scancell, CR UK publish joint vaccine update
SCIB2 is to be administered using a new nanoparticle formulation in a planned Phase I/II clinical trial.
Read More
UK regulatory approval for SCIB1 phase II advanced melanoma trial
The study is designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate.
Read More
- Tremfya data show sustained remission in ulcerative colitis through 3 years
- Brensocatib becomes first licensed treatment for non‑cystic fibrosis bronchiectasis
- Lario Therapeutics awarded $2.4m to advance calcium channel platform
- Mikrobiomik secures approval for gut‑microbiota therapy for C difficile infection
- Exdensur approved in EU for severe asthma and CRSwNP
